New Blood Test: Predicts Risk of Future Heart Attack

Guest Bio: Doug Harrington, MD

Dr. Harrington has over 25 years of experience in the commercialization of healthcare technology. Prior to joining Aviir in 2008, he served as CEO and Lab Director at Specialty Laboratories, Inc. and WM Laboratories, Inc.; as Chairman & CEO at Chromavision Medical Systems, Inc.; and as President and Lab Director at Nichols Institute.

Dr. Harrington is licensed in a number of states including New York, holding CQ's in Molecular and Biochemical Genetics. In addition, he has successfully taken a number of new molecular technologies through state and federal regulatory approval. Dr. Harrington has been a board member of 14 companies including directorships and managerial positions at Axela Biosensors (Board Member), Affymetrix, Navigenics, Inc. (Consulting Laboratory Director), CLED (Chairman) and USC Keck School of Medicine (Clinical Professor of Pathology).

He holds multiple professional affiliation memberships including the American Medical Association, the American Society of Clinical Pathologists, the College of American Pathologists, the Association for Molecular Pathology, and the International Academy of Pathology. Dr. Harrington received his B.A. in Molecular Biology and M.D. from the University of Colorado. He is Board Certified in Anatomic and Clinical Pathology and Hematology and has authored numerous peer-reviewed publications.